Kyntra Bio to Participate in Upcoming Investor Conferences

Kyntra Bio (Nasdaq: KYNB), formerly known as FibroGen (Nasdaq: FGEN), has announced its participation in two upcoming investor conferences. The first, the Oppenheimer 36th Annual Healthcare Life Sciences Conference, will be held virtually on February 26, 2026, from 2:40 to 3:10 PM ET. The second event, the Leerink Global Healthcare Conference, is scheduled for March 11, 2026, in Miami, FL, from 2:20 to 2:50 PM ET. During these conferences, Kyntra’s management team will also be available for one-on-one meetings with interested investors.

Kyntra Bio is focused on developing innovative therapies in oncology and rare diseases. It’s notable for its lead product, Roxadustat (EVRENZO™), which is approved in Europe, Japan, and several other countries for treating anemia in chronic kidney disease (CKD) patients, both on and off dialysis. Currently, the company is evaluating a Phase 3 trial for Roxadustat specifically aimed at anemia related to lower-risk myelodysplastic syndromes (LR-MDS) in the United States.

Additionally, Kyntra is developing FG-3246 (FOR46), a first-in-class antibody-drug conjugate targeting CD46, which is in Phase 2 trials for metastatic castration-resistant prostate cancer. This program includes work on FG-3180, a biomarker designed to aid in treatment targeting.

Investors can find replays of the presentations on Kyntra Bio's website under the Events & Presentations section, where content will be available for 90 days after the events. For more information, interested parties can visit www.kyntrabio.com or contact David DeLucia, the Senior Vice President and Chief Financial Officer, via email for inquiries.

Kyntra Bio (Nasdaq: KYNB) is gearing up for several significant investor conferences, providing an excellent opportunity for stakeholders to engage with the management team as they discuss the advances in their therapeutic portfolio. Investors should pay close attention, as participation in these conferences often signals impending developments that can influence stock performance.

The upcoming presentations at the Oppenheimer 36th Annual Healthcare Life Sciences Conference and the Leerink Global Healthcare Conference are pivotal. Kyntra Bio's management will present their progress on key drugs, particularly Roxadustat, which is already approved in major markets. The company is additionally pursuing Phase 3 trials for Roxadustat in relation to lower-risk myelodysplastic syndromes (LR-MDS), which could enhance its market position and revenue potential.

Moreover, the spotlight on FG-3246, a novel antibody-drug conjugate currently in Phase 2 development for metastatic castration-resistant prostate cancer, is critical for future growth. The dual approach of advancing a therapeutic agent alongside a targeted PET biomarker (FG-3180) could strengthen Kyntra's strategic position in personalized medicine, appealing to a broader investor base interested in innovative oncology solutions.

As Kyntra Bio makes its presentations available via webcasts, investors should carefully analyze management’s insights and guidance during the Q&A sessions. Engaging in one-on-one meetings with Kyntra's management can provide deeper insights and clarity on future pipelines and strategic initiatives.

In the aftermath of these conferences, investors should monitor stock reactions and any changes in analyst ratings or market sentiment. Given the anticipated advancements in their oncology portfolio, Kyntra Bio presents a compelling case for investment, particularly for those interested in biopharmaceuticals at the forefront of critical therapeutic areas. As always, conduct due diligence and consider potential risks when making investment decisions.